Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

The Role of Ampligen in Strategic Therapeutic Intervention (STI) of HAART

ClinicalTrials.gov ID: NCT00035893

Public ClinicalTrials.gov record NCT00035893. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 4:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

The Role of Ampligen in Strategic Therapeutic Intervention (STI) of Highly Active Anti-Retroviral Therapy (HAART): A Multi-Center, Randomized, Controlled Study of Ampligen Potentiation of the HAART-Free Interval.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is an open-label, prospective, randomized, controlled study of the safety and efficacy including clinical, immunologic, and virologic assessments of adding Ampligen to a Strategic Therapeutic Intervention (STI) of HAART in patients with plasma HIV RNA \< 50 copies/ml (PCR) and CD4 levels \> 400.

Study identification

NCT ID
NCT00035893
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
AIM ImmunoTech Inc.
Industry
Enrollment
40 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 30, 2001
Primary completion
Jul 31, 2006
Completion
Jul 31, 2006
Last update posted
Apr 16, 2013

2001 – 2006

United States locations

U.S. sites
10
U.S. states
6
U.S. cities
10
Facility City State ZIP Site status
Orange County Center for Special Immunology Fountain Valley California 92708
AltaMed Health Services Corporation Los Angeles California 90022
Circle Medical Center Norwalk Connecticut 06851
Dupont Circle Physicians Group Washington D.C. District of Columbia 20009
Julia Torres, MD Fort Lauderdale Florida 33306
Allied Clinical Trials Miami Florida 33156
Scott Ubillos, MD Tampa Florida 33607
St. Michael's Medical Center Newark New Jersey 07102
Christopher Lucasti, D.O. Somers Point New Jersey 08244
W. Chris Woodward, DO Reading Pennsylvania 19601

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00035893, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 16, 2013 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00035893 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →